OPTHEA LTD (SP.ADR/8) (UKJ2) - Total Assets
Based on the latest financial reports, OPTHEA LTD (SP.ADR/8) (UKJ2) holds total assets worth €145.77 Million EUR (≈ $170.42 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
OPTHEA LTD (SP.ADR/8) - Total Assets Trend (2022–2025)
This chart illustrates how OPTHEA LTD (SP.ADR/8)'s total assets have evolved over time, based on quarterly financial data. Also see OPTHEA LTD (SP.ADR/8) market cap and net worth for the company's overall valuation and market capitalisation.
OPTHEA LTD (SP.ADR/8) - Asset Composition Analysis
Current Asset Composition (June 2025)
OPTHEA LTD (SP.ADR/8)'s total assets of €145.77 Million consist of 100.0% current assets and 0.0% non-current assets. Review OPTHEA LTD (SP.ADR/8) (UKJ2) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 85.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how OPTHEA LTD (SP.ADR/8)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See OPTHEA LTD (SP.ADR/8) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OPTHEA LTD (SP.ADR/8)'s current assets represent 100.0% of total assets in 2025, an increase from 99.8% in 2022.
- Cash Position: Cash and equivalents constituted 85.3% of total assets in 2025, up from 74.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OPTHEA LTD (SP.ADR/8) Competitors by Total Assets
Key competitors of OPTHEA LTD (SP.ADR/8) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
OPTHEA LTD (SP.ADR/8) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.57 | 2.94 | - |
| Quick Ratio | 1.57 | 2.94 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €52.38 Million | €124.14 Million | - |
OPTHEA LTD (SP.ADR/8) - Advanced Valuation Insights
This section examines the relationship between OPTHEA LTD (SP.ADR/8)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.38 |
| Latest Market Cap to Assets Ratio | 9.03 |
| Asset Growth Rate (YoY) | -69.9% |
| Total Assets | €56.80 Million |
| Market Capitalization | $512.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OPTHEA LTD (SP.ADR/8)'s assets at a significant premium (9.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: OPTHEA LTD (SP.ADR/8)'s assets decreased by 69.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OPTHEA LTD (SP.ADR/8) (2022–2025)
The table below shows the annual total assets of OPTHEA LTD (SP.ADR/8) from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €56.80 Million ≈ $66.40 Million |
-69.91% |
| 2024-06-30 | €188.79 Million ≈ $220.72 Million |
+91.39% |
| 2023-06-30 | €98.64 Million ≈ $115.32 Million |
+64.27% |
| 2022-06-30 | €60.05 Million ≈ $70.20 Million |
-- |
About OPTHEA LTD (SP.ADR/8)
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more